Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization

Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie K. Ritchey, John F. DiPersio

Blood (2023) 142 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2023-181174

Published: 2023

Journal Articles

Identifying Surface Protein Markers for AML Immunotherapy

Omar M. Ibrahim, Michael P. Rettig, Ezhilarasi Chendamarai, Reyka G. Jayasinghe, Li Ding, John DiPersio

Blood (2023) 142 (Supplement 1): 6809.

https://doi.org/10.1182/blood-2023-187831

Published: 2023

Journal Articles

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Joseph C. Rimando, Ezhilarasi Chendamarai, Michael P. Rettig, Reyka Jayasinghe, Matthew J. Christopher, Julie K. Ritchey, Stephanie Christ, Miriam Y. Kim, Ezio Bonvini, John F. DiPersio

Blood (2023) 141 (14): 1718–1723.

https://doi.org/10.1182/blood.2022017795

Published: 2023

Includes: Supplemental data

Journal Articles

Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization

Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie K. Ritchey, John F. DiPersio

Blood (2022) 140 (Supplement 1): 4477–4478.

https://doi.org/10.1182/blood-2022-159734

Published: 2022

Journal Articles

Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma

Ezhilarasi Chendamarai, Julie K. Ritchey, Leah Gehrs, Michael P. Rettig, Sai Mukund Ramakrishnan, Christopher A Miller, George Cox, Lana Anderson, Timothy J Ley, John F. DiPersio

Blood (2022) 140 (Supplement 1): 7345–7346.

https://doi.org/10.1182/blood-2022-167415

Published: 2022

Journal Articles

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Dilan Anil Patel, Ezhilarasi Chendamarai, Julie K. Ritchey, Michael P. Rettig, Leah Gehrs, Paul Moore, Ralph F. Alderson, Ezio Bonvini, Matthew Christopher, John F. DiPersio

Blood (2022) 140 (Supplement 1): 8795–8796.

https://doi.org/10.1182/blood-2022-156943

Published: 2022

Journal Articles

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Daniel Cancilla, BS, Haresh Thakellapalli, Marvin J Meyers, PhD, Michael P. Rettig, PhD, Ezhilarasi Chendamarai, PhD, Stephanie Christ, MS, Darja Karpova, PhD, Peter G Ruminski, BS, Julie K. Ritchey, Dwight M. Morrow, PhD, Michael Prinsen, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 1916.

https://doi.org/10.1182/blood-2019-124373

Published: 2019

Journal Articles

Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice

Armin Ghobadi, Michael P. Rettig, Matthew S. Holt, Julie K. Ritchey, Krista Kennerly, Ezhilarasi Chendamarai, Linda Eissenberg, John F. DiPersio

Blood (2018) 131 (23): 2594–2596.

https://doi.org/10.1182/blood-2017-10-811620

Published: 2018

Journal Articles

Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist

Moses O. Evbuomwan, Richard F Heier, BS, Darja Karpova, PhD, Stephanie Christ, MS, Ezhilarasi Chendamarai, PhD, Michael P Rettig, PhD, Linda G Eissenberg, PhD, Stacy D Arnett, PhD, Julie Ritchey, Marvin J Meyers, PhD, Peter G Ruminski, BS, David W Griggs, PhD, Dwight Morrow, PhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 3197.

https://doi.org/10.1182/blood.V130.Suppl_1.3197.3197

Published: 2017

Journal Articles

Generation and Characterization of Murine Allogeneic T Cell Resistant APL Cells

Ezhilarasi Chendamarai, PhD, Michael P Rettig, PhD, Gue Su Chang, PhD, Allegra A Petti, PhD, Christopher A Miller, PhD, Julie Ritchey, Lukas D Wartman, MD, Timothy J Ley, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 3170.

https://doi.org/10.1182/blood.V130.Suppl_1.3170.3170

Published: 2017

Journal Articles

Arsenic Trioxide Resistance: More to It Than Mutations in PML-RARα

Ansu Abu Alex, MSc, Ezhilarasi Chendamarai, PhD, Saravanan Ganesan, MSc, Nithya Balasundaram, MSc, Hamenth Kumar Palani, MSc, Sachin David, MSc, Vikram Mathews, MD

Blood (2014) 124 (21): 3605.

https://doi.org/10.1182/blood.V124.21.3605.3605

Published: 2014

Journal Articles

Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML

Ambrose Campbell, Ezhilarasi Chendamarai, PhD, Matthew Holt, Julie Prior, Linda Eissenberg, PhD, Michael P. Rettig, PhD, Gregoire Vuagniaux, PhD, Claudio Zanna, PhD, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 5296.

https://doi.org/10.1182/blood.V124.21.5296.5296

Published: 2014

Journal Articles

Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia

Saravanan Ganesan, MSc, Ansu Abu Alex, MSc, Ezhilarasi Chendamarai, PhD, Nithya Balasundaram, MSc, Hamenth Kumar Palani, MSc, Sachin David, MSc, Jayandharan G Rao, PhD, Aby Abraham, MD, Auro Viswabandya, MD, Biju George, MD, Alok Srivastava, MD, Poonkuzhali Balasubramanian, PhD, Rose Ann Padua, PhD, Christine Chomienne, MD PhD, Vikram Mathews, MD

Blood (2014) 124 (21): 3741.

https://doi.org/10.1182/blood.V124.21.3741.3741

Published: 2014

Journal Articles

Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance

Ezhilarasi Chendamarai, Ansu Abu Alex, MSc, Saravanan Ganesan, MSc, Vandana Kamath, MD, Sukesh C Nair, MD, Nancy Beryl Janet, MSc, Vivi M Srivastava, MD, Kavitha M Lakshmi, MSc, Poonkuzhali Balasubramanian, Ph.D, Rayaz Ahmed, MD, Aby Abraham, MD, Auro Viswabandya, MD, Biju George, MD, Alok Srivastava, MD, Vikram Mathews

Blood (2012) 120 (21): 1390.

https://doi.org/10.1182/blood.V120.21.1390.1390

Published: 2012

Journal Articles

Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission

Ansu Abu Alex, MSc, Saravanan Ganesan, MSc, Poonkuzhali Balasubramanian, Ph.D, Rayaz Ahmed, MD, Aby Abraham, MD, Auro Viswabandya, MD, Biju George, MD, Ezhilarasi Chendamarai, Alok Srivastava, MD, Vikram Mathews

Blood (2012) 120 (21): 3552.

https://doi.org/10.1182/blood.V120.21.3552.3552

Published: 2012

Journal Articles

Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes

Blood (2012) 120 (21): 783.

https://doi.org/10.1182/blood.V120.21.783.783

Published: 2012

Journal Articles

Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients

Saravanan Ganesan, MSc, Ezhilarasi Chendamarai, Ansu Abu Alex, MSc, Sachin David, MSc, Giridhara R Jayandharan, Ph.D, Poonkuzhali Balasubramanian, Ph.D, Rayaz Ahmed, MD, Aby Abraham, MD, Auro Viswabandya, MD, Biju George, MD, Alok Srivastava, MD, Vikram Mathews

Blood (2012) 120 (21): 3607.

https://doi.org/10.1182/blood.V120.21.3607.3607

Published: 2012

Journal Articles

Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy

Ezhilarasi Chendamarai, Poonkuzhali Balasubramanian, Biju George, Auro Viswabandya, Aby Abraham, Rayaz Ahmed, Ansu Abu Alex, Saravanan Ganesan, Kavitha M. Lakshmi, Usha Sitaram, Sukesh Chandran Nair, Mammen Chandy, Nancy Beryl Janet, Vivi M. Srivastava, Alok Srivastava, Vikram Mathews

Blood (2012) 119 (15): 3413–3419.

https://doi.org/10.1182/blood-2011-11-393264

Published: 2012

Includes: Supplemental data

Journal Articles

Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy

Ezhilarasi Chendamarai, MSc, Poonkuzhali Balasubramanian, Ph.D, Biju George, MD, Kavitha M Lakshmi, MSc, Auro Viswabandhya, Aby Abraham, MD, Rayaz Ahmed, MD, Ansu Abu Alex, MSc, Saravanan Ganesan, MSc, Mammen Chandy, MD, Alok Srivastava, MD, Vikram Mathews, MD

Blood (2011) 118 (21): 941.

https://doi.org/10.1182/blood.V118.21.941.941

Published: 2011

Journal Articles

Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data

Saravanan Ganesan, MSc, Ezhilarasi Chendamarai, MSc, Jayandharan G Rao, PhD, Sangeetha Hareendran, MSc, Ansu Abu Alex, MSc, Rayaz Ahmed, MD, Aby Abraham, MD, Auro Viswabandhya, Biju George, MD, Alok Srivastava, MD, Vikram Mathews, MD

Blood (2011) 118 (21): 947.

https://doi.org/10.1182/blood.V118.21.947.947

Published: 2011

NARROW

Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization

Identifying Surface Protein Markers for AML Immunotherapy

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization

Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice

Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist

Generation and Characterization of Murine Allogeneic T Cell Resistant APL Cells

Arsenic Trioxide Resistance: More to It Than Mutations in PML-RARα

Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML

Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia

Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance

Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission

Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes

Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients

Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy

Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy

Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only